183 related articles for article (PubMed ID: 24113164)
1. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells.
Okada T; Murata K; Hirose R; Matsuda C; Komatsu T; Ikekita M; Nakawatari M; Nakayama F; Wakatsuki M; Ohno T; Kato S; Imai T; Imamura T
Sci Rep; 2013 Oct; 3():2899. PubMed ID: 24113164
[TBL] [Abstract][Full Text] [Related]
2. FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect.
Yu H; Wang H; Qie A; Wang J; Liu Y; Gu G; Yang J; Zhang H; Pan W; Tian Z; Wang C
Cancer Sci; 2021 Nov; 112(11):4655-4668. PubMed ID: 34533854
[TBL] [Abstract][Full Text] [Related]
3. Histamine H1 receptor antagonists selectively kill cisplatin-resistant human cancer cells.
Matsumoto N; Ebihara M; Oishi S; Fujimoto Y; Okada T; Imamura T
Sci Rep; 2021 Jan; 11(1):1492. PubMed ID: 33452347
[TBL] [Abstract][Full Text] [Related]
4. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity.
Feng LL; Shen FR; Zhou JH; Chen YG
Gene; 2019 May; 696():105-112. PubMed ID: 30738960
[TBL] [Abstract][Full Text] [Related]
5. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
Li R; Liu GZ; Luo SY; Chen R; Zhang JX
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
[TBL] [Abstract][Full Text] [Related]
6. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
[TBL] [Abstract][Full Text] [Related]
7. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
8. BRSK1 confers cisplatin resistance in cervical cancer cells via regulation of mitochondrial respiration.
Liu G; Li L; Shang D; Zhou C; Zhang C
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8803-8815. PubMed ID: 37140697
[TBL] [Abstract][Full Text] [Related]
9. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
Shu XR; Wu J; Sun H; Chi LQ; Wang JH
Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
[TBL] [Abstract][Full Text] [Related]
10. AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer.
Bi L; Ma F; Tian R; Zhou Y; Lan W; Song Q; Cheng X
Gene; 2018 Feb; 644():148-154. PubMed ID: 29126926
[TBL] [Abstract][Full Text] [Related]
11. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2.
Shi F; Su J; Liu Z; Wang J; Wang T
J Cell Biochem; 2019 Sep; 120(9):15018-15026. PubMed ID: 31017720
[TBL] [Abstract][Full Text] [Related]
12. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
13. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
Feng Y; Zou W; Hu C; Li G; Zhou S; He Y; Ma F; Deng C; Sun L
Arch Biochem Biophys; 2017 Jun; 623-624():20-30. PubMed ID: 28495512
[TBL] [Abstract][Full Text] [Related]
14. Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer.
Wang T; Liu Z; Shi F; Wang J
Mol Cell Biochem; 2016 Feb; 413(1-2):179-87. PubMed ID: 26820938
[TBL] [Abstract][Full Text] [Related]
15. MiR-181a Promotes Apoptosis and Reduces Cisplatin Resistance by Inhibiting Osteopontin in Cervical Cancer Cells.
Xu X; Jiang X; Chen L; Zhao Y; Huang Z; Zhou H; Shi M
Cancer Biother Radiopharm; 2019 Nov; 34(9):559-565. PubMed ID: 31436472
[No Abstract] [Full Text] [Related]
16. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of mRNA Decapping protein 4 (EDC4) interacts with replication protein a (RPA) and contributes to Cisplatin resistance in cervical Cancer by alleviating DNA damage.
Wu X; Zhong Y; Chen Q; Zhang X; Zhang H
Hereditas; 2020 Oct; 157(1):41. PubMed ID: 33054858
[TBL] [Abstract][Full Text] [Related]
18. PDGF α receptor is a mediator for Cisplatin-induced Met expression.
Kina S; Phonaphonh T; Liang F; Kuang H; Arasaki A; Arakaki K; Nakasone T; Sunakawa H
Eur J Pharmacol; 2013 Jan; 699(1-3):227-32. PubMed ID: 23200895
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
